NCT06182384已完成1 期
A Single-center, Randomized, Open, Two-period, Two-sequence Crossover Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- After a single subcutaneous injection of SHR-1314, assess injection site pain by VISUAL ANALOG SCALE at immediately after administration, 1 h, 48 h, Day 5 and Day 8, the results ranger from 0 to 10 cm, with higher scores indicating greater pain
研究概览
简要总结
The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntary signing of informed consent form before related activities of the experiment and understanding of the procedures and methods of the experiment, willing to strictly follow the clinical trial protocol to complete the experiment.
- •Both men and women are eligible, aged 18 to 45 years old (inclusive, as determined at the time of signing informed consent form).
- •Body mass index (BMI) is between 18 and 25 kg/m2 (inclusive), with male weight ≥ 50 kg and female weight ≥ 45 kg.
- •Subjects with normal physical examination results and with normal laboratory results (blood, chemistry, urine, drug screening, coagulation function test), ECG and X-ray chest test are normal or with certain abnormal without clinical significance.
排除标准
- •Having a history of any clinically significant disease or condition that the investigator believes may affect the trial results, including but not limited to a history of cardiovascular, endocrine, neurological, digestive, urinary, hematological, immunological, metabolic diseases, or existing diseases in these systems.
- •Have a history of drug or other allergies, or are likely to be allergic to the investigational drug or any component of the investigational drug as determined by the investigator.
- •History or current infection with human immunodeficiency virus (HIV) or hepatitis C; or current hepatitis B infection or syphilis.
- •History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years.
- •History of chronic or recurrent infectious disease, or evidence of active or latent tuberculosis infection.
- •Clinical symptoms, signs, laboratory tests, or X-rays suggest active or latent tuberculosis Tuberculosis infected persons;
- •Those who have participated in any clinical study for any drug or medical device within 3 months before screening
- •Those who have received live attenuated vaccine within 12 weeks prior to screening or plan to receive live attenuated vaccine during the trial.
- •Blood donation or blood loss ≥ 400 mL within 8 weeks prior to screening, or receiving blood transfusion within 8 weeks;
- •Venous blood collection difficulties or physical conditions can not withstand blood collection;
- •Had used other drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines and dietary supplements) in the 2 weeks before screening;
- •Current or past alcoholics (drinking more than 14 standard units per week) 1 Standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who cannot abstain from alcohol during the trial;
- •The average daily smoking amount in the 3 months before the test was ≥ 10 cigarettes; Or cannot stop using any tobacco products during the trial
- •History or evidence of ongoing alcohol or drug abuse, within the last six months before Baseline.
- •Female and male subjects who are fertile (defined as having the physical conditions necessary to become pregnant) who plan to become pregnant or donate sperm/egg within 20 weeks of using the study drug (greater than 5 half-lives) or who do not wish to use contraception; Female subjects who are fertile but have not used contraception in the 30 days prior to randomization;
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- •Subjects judged by the investigator as unsuitable for participating in this study.
研究组 & 干预措施
Sequence A
Experimental
干预措施: SHR-1314 (Drug)
Sequence B
Experimental
干预措施: SHR-1314 (Drug)
结局指标
主要结局
After a single subcutaneous injection of SHR-1314, assess injection site pain by VISUAL ANALOG SCALE at immediately after administration, 1 h, 48 h, Day 5 and Day 8, the results ranger from 0 to 10 cm, with higher scores indicating greater pain
时间窗: Day 1 to Day 8 after each administration
After a single subcutaneous injection of SHR-1314, the incidence rate of injection site reaction at 1 h, 48 h, Day 5 and Day 8
时间窗: Day 1 to Day 8 after each administration
次要结局
- After a single subcutaneous injection of SHR-1314, the PK parameters of plasma SHR-1314: Area Under the Concentration versus time curve (AUC0-t)(Day 1 to Day 28)
- Immunogenicity indicators: The rate of anti-SHR-1314 antibodies(Start of treatment up to Day 43)
- After a single subcutaneous injection of SHR-1314, the PK parameters of plasma SHR-1314: Time to maximum concentration (Tmax)(Day 1 to Day 28)
- After a single subcutaneous injection of SHR-1314, the PK parameters of plasma SHR-1314: Maximum Concentration (Cmax)(Day 1 to Day 28)
- Safety indicators: The rate of adverse events (AE, including Injection site reactions), serious adverse events (SAE)(Screening period up to Day 43)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Study of SHR0410 in Hemodialysis Patients With PruritusPruritusNCT04317209Jiangsu HengRui Medicine Co., Ltd.54
进行中（未招募）
1 期
Safety and Tolerability of SHR-1918 in Healthy SubjectsHyperlipemiaNCT05432544Beijing Suncadia Pharmaceuticals Co., Ltd72
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy SubjectsPrevention of Arterial and Venous ThrombosisNCT05369767Beijing Suncadia Pharmaceuticals Co., Ltd64
Unknown
1 期
A Trial of HR17031 Injection With Hepatic InsufficiencyImproved Glycemic Control in Patients With Type 2 DiabetesNCT05151705Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy SubjectsType 2 DiabetesNCT06654960Fujian Shengdi Pharmaceutical Co., Ltd.20